Table 3.
Sequential changes in secondary clinical scores after intravenous immunoglobulin administration
| a. Baselinea | b. 2 weeks | c. 4 weeks | d. 6 weeks | e. 8 weeks | p values* | ||||
|---|---|---|---|---|---|---|---|---|---|
| b–a | c–a | d–a | e–a | ||||||
| Number of muscles with MMT scores of three or less | |||||||||
| Group A (n = 8) | 11.0 ± 6.1 | 7.0 ± 4.4 | 5.5 ± 4.3 | 5.3 ± 3.8 | 5.1 ± 3.3 | ||||
| Group B (n = 8) | 7.8 ± 4.8 | 6.0 ± 4.6 | 4.1 ± 4.0 | 4.3 ± 3.8 | 4.3 ± 3.8 | ||||
| Group C (n = 7) | 10.9 ± 9.4 | 8.7 ± 6.2 | 7.9 ± 5.2 | 7.4 ± 5.3 | 5.3 ± 3.2 | ||||
| All patients (n = 23) | 9.8 ± 6.8 | 7.2 ± 5.0 | 5.7 ± 4.6 | 5.6 ± 4.3 | 4.9 ± 3.3 | 0.004 | 0.002 | 0.001 | <0.001 |
| Visual analogue scale | |||||||||
| Group A (n = 8) | 64.75 ± 32.19 | 59.75 ± 33.72 | 59.13 ± 30.43 | 57.00 ± 29.75 | 55.50 ± 33.55 | ||||
| Group B (n = 8) | 77.63 ± 21.49 | 71.13 ± 21.75 | 68.63 ± 26.28 | 70.00 ± 23.72 | 70.81 ± 24.28 | ||||
| Group C (n = 7) | 59.43 ± 31.41 | 56.29 ± 29.83 | 49.71 ± 34.44 | 53.29 ± 28.00 | 51.43 ± 28.26 | ||||
| All patients (n = 23) | 67.61 ± 28.40 | 62.65 ± 28.23 | 59.57 ± 29.98 | 60.39 ± 26.98 | 59.59 ± 28.92 | 0.005 | 0.002 | 0.004 | 0.021 |
| Modified Barthel index | |||||||||
| Group A (n = 8) | 87.1 ± 15.2 | 89.5 ± 11.2 | 92.1 ± 8.0 | 92.3 ± 7.9 | 93.4 ± 6.9 | ||||
| Group B (n = 8) | 80.0 ± 26.9 | 84.5 ± 25.3 | 85.1 ± 25.6 | 87.3 ± 21.4 | 87.4 ± 21.2 | ||||
| Group C (n = 7) | 85.9 ± 10.7 | 86.4 ± 10.8 | 91.1 ± 8.0 | 91.1 ± 8.0 | 91.9 ± 6.8 | ||||
| All patients (n = 23) | 84.3 ± 18.6 | 86.8 ± 16.7 | 89.4 ± 16.0 | 90.2 ± 13.7 | 90.8 ± 13.3 | 0.107 | 0.020 | 0.009 | 0.005 |
MMT manual muscle testing
* Paired t test for change from baseline
aBaseline scores were those immediately before intravenous immunoglobulin administration